Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Nelson

Showing results (421-430 of 521) with videos related to

Pageof 53
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|October 29, 2015
HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscapeNancy Reau, Michael W Fried, David R Nelson, et al.
Hepatology (Baltimore, Md.)|August 13, 2008
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirinMichael W Fried, Donald M Jensen, Maribel Rodriguez-Torres, et al.
The Journal of Infectious Diseases|November 26, 2015
L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B SubstitutionsEvguenia S Svarovskaia, Edward Gane, Hadas Dvory-Sobol, et al.
The New England Journal of Medicine|April 12, 2014
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirinJordan J Feld, Kris V Kowdley, Eoin Coakley, et al.
The Lancet. Gastroenterology & Hepatology|June 4, 2017
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trialAnnette Bruchfeld, David Roth, Paul Martin, et al.
Journal of Viral Hepatitis|April 14, 2019
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosisFred Poordad, Shahriar Sedghi, Paul J Pockros, et al.
The Plant Journal : for Cell and Molecular Biology|February 25, 2025
Chromosome-level assemblies of Amaranthus palmeri, Amaranthus retroflexus, and Amaranthus hybridus allow for genomic comparisons and identification of a sex-determining regionDamilola A Raiyemo, Jacob S Montgomery, Luan Cutti, et al.
Plos One|December 27, 2024
Transcriptomic resources for Bagrada hilaris (Burmeister), a widespread invasive pest of BrassicalesMichael E Sparks, David R Nelson, Robert L Harrison, et al.
Journal of Viral Hepatitis|March 5, 2021
Willingness to participate in research among black patients with liver disease: A national cross-sectional studyF Hunter McGuire, Kat André, Minyone L Bradsher, et al.
Scientific Reports|July 2, 2015
Diversity and evolution of cytochrome P450 monooxygenases in OomycetesMopeli Marshal Sello, Norventia Jafta, David R Nelson, et al.
Pageof 53

Showing results (421-430 of 521) with videos related to

Sort By:
Pageof 53
Liver International : Official Journal of the International Association for the Study of the Liver|October 29, 2015
HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscapeNancy Reau, Michael W Fried, David R Nelson, et al.
Hepatology (Baltimore, Md.)|August 13, 2008
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirinMichael W Fried, Donald M Jensen, Maribel Rodriguez-Torres, et al.
The Journal of Infectious Diseases|November 26, 2015
L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B SubstitutionsEvguenia S Svarovskaia, Edward Gane, Hadas Dvory-Sobol, et al.
The New England Journal of Medicine|April 12, 2014
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirinJordan J Feld, Kris V Kowdley, Eoin Coakley, et al.
The Lancet. Gastroenterology & Hepatology|June 4, 2017
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trialAnnette Bruchfeld, David Roth, Paul Martin, et al.
Journal of Viral Hepatitis|April 14, 2019
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosisFred Poordad, Shahriar Sedghi, Paul J Pockros, et al.
The Plant Journal : for Cell and Molecular Biology|February 25, 2025
Chromosome-level assemblies of Amaranthus palmeri, Amaranthus retroflexus, and Amaranthus hybridus allow for genomic comparisons and identification of a sex-determining regionDamilola A Raiyemo, Jacob S Montgomery, Luan Cutti, et al.
Plos One|December 27, 2024
Transcriptomic resources for Bagrada hilaris (Burmeister), a widespread invasive pest of BrassicalesMichael E Sparks, David R Nelson, Robert L Harrison, et al.
Journal of Viral Hepatitis|March 5, 2021
Willingness to participate in research among black patients with liver disease: A national cross-sectional studyF Hunter McGuire, Kat André, Minyone L Bradsher, et al.
Scientific Reports|July 2, 2015
Diversity and evolution of cytochrome P450 monooxygenases in OomycetesMopeli Marshal Sello, Norventia Jafta, David R Nelson, et al.
Pageof 53